Forget Cannabis: Psychedelic Stocks Could Be the Next Big Thing for the Decade

Did you miss the epic cannabis rally in 2018? Don’t bother. These psychedelic stocks could be next up to break the roof.

Pills spilling out of a prescription pot

Image source: Getty Images.

Cannabis stocks made enormous wealth for its shareholders in 2018 and 2019 after being legalized in Canada. If you missed the rally, then the psychedelic stocks could be next up for a breakout.

Psychedelic stocks in 2020

Regulatory support and encouraging research outcomes sent these stocks through the roof late last year. To name a few, Numinus Wellness (TSXV:NUMI) is a Canada-based healthcare company that’s working around psychedelic therapies. NUMI soared a notable 510% last year. Another stock, Mind Medicine, surged a massive 860% in 2020.

In late 2019, the U.S. FDA (Food and Drug Administration) showed a ray of hope for the industry. It affirmed that psychedelic Psilocybin could be a breakthrough therapy for depression and mental disorders.

Psilocybin is a hallucinogenic compound generally found in a type of fungi that’s as popular as magic mushrooms. Studies have shown that this compound is effective in treating mental disorders, anxiety, depression, and addictions.

Strong growth prospects

According to research, the psychedelic industry is expected to grow to $6.85 billion by 2027. That’s more than 16% compounded annually from its current size. The growth potential is significantly large considering the globally rising depression and mental disorder cases.

Interestingly, regulators showed their support for the use of Psilocybin recently, which further boosted the industry sentiment. In November last year, Health Canada approved the therapeutic consumption of Psilocybin for patients with severe depression.

Oregon also became the first U.S. state to allow medical use of psychedelics last year. Industry experts are hopeful for more regulatory support going forward. If that happens, the industry growth will remarkably accelerate, and psychedelic stocks could soon skyrocket.

Looking to bet on psychedelic stocks?

Like biotech stocks, psychedelics are also extremely volatile. Numinus Wellness has been no different. It is the first company to receive a licence from Health Canada to produce and harvest magic mushrooms and extract and research Psilocybin. Numinus reported $229,188 in revenues for the quarter ended November 30, 2020, indicating 70% growth year over year. It is a loss-making company at the moment.

Though growth potential might look attractive, psychedelic stocks could be highly risky. Their smaller size and underlying uncertainties could make their volatility hard for investors’ appetite.

$1.2 billion Mind Medicine is a Canadian neuro-pharma company that’s working in this domain. It has several drugs in various stages of clinical trials. It is also working on developing a therapy using Psilocybin. The efficacy results of the subsequent trials will be interesting to see.

The first psychedelic-drug companies ETF began trading in Canada last week. The Horizons Psychedelic Fund is currently trading at $9.4 and tracks the North American Psychedelic Index. Some of the top holdings include Compass Pathways, Numinus Wellness, and Mind Medicine that forms 10%, 9%, and 9% in the fund, respectively. Johnson & Johnson is also a part with a 5% weighting.

Bottom line

Psychedelic drugs are an industry that is taking birth. The regulations and research around it will pave the way for it. The COVID-19 pandemic has substantially added to mental health problems, which should act as a catalyst for the industry.

Notably, psychedelics are prominently used for therapeutic purposes, and the recreational use seems very low, as of now. So, one can expect relatively faster approvals from regulators, unlike cannabis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vineet Kulkarni has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson.

More on Stocks for Beginners

Stocks for Beginners

Canadian Investors: 2 Oversold Canadian Stocks to Buy Now

These Canadian stocks continue to trade in oversold territory, creating a prime opportunity for investors to pick them up today.

Read more »

analyze data
Stocks for Beginners

Sun Life Financial: A Good Stock for Most Investors

Sun Life Financial is a quality business that can deliver resilient results. It could be a good long-term investment.

Read more »

exchange-traded funds
Stocks for Beginners

You Don’t Have to Pick a Winner in the U.S. Stock Market: Here’s Why

Just buy an S&P 500 Index ETF and chill.

Read more »

A solar cell panel generates power in a country mountain landscape.
Energy Stocks

2 Renewable Energy Stocks That Could Put You in the Green

There's no shortage of renewable energy stocks to add to your portfolio. Here's a duo that will point your portfolio…

Read more »

Dollar symbol and Canadian flag on keyboard
Stocks for Beginners

2 Safe Canadian Stocks to Buy in September 2023

These safe Canadian stocks could keep yielding steady returns on your investments, even in difficult economic environments.

Read more »

A bull and bear face off.
Stocks for Beginners

Where to Invest $10,000 in a Bear Market

To ensure safety of your money in a bear market, stick with GIC-type investments. Consider putting long-term capital in quality…

Read more »

A tractor harvests lentils.
Dividend Stocks

Nutrien Stock: Create Passive Income With No Start-Up Costs

Creating passive income can be difficult if you don't have cash on hand, so start making some immediately and then…

Read more »

edit Business accounting concept, Business man using calculator with computer laptop, budget and loan paper in office.
Stocks for Beginners

Is Maple Leaf Foods Stock a Buy in September 2023?

Here’s why MFI stock looks attractive to buy now for the long term, despite ongoing challenges.

Read more »